Browsing Tag
clinical trials
131 posts
Novo Nordisk advances amycretin to phase 3 after early data show weight loss of up to 24% in obesity trials
Novo Nordisk moves amycretin to phase 3 after early trials show up to 24% weight loss. See what makes this dual-receptor drug a next-gen obesity contender.
AtomVie Global Radiopharma partnering with TerraPower Isotopes to secure actinium-225 for global cancer therapy development
AtomVie Global Radiopharma signs agreement with TerraPower Isotopes to secure actinium-225 supply, aiming to advance CDMO-based cancer radiotherapies.
Unicycive (NASDAQ: UNCY) hit by FDA manufacturing concerns ahead of oxylanthanum carbonate decision
Unicycive’s NDA for oxylanthanum carbonate faces FDA manufacturing concerns. Key decision expected June 28. Read the stock outlook and next steps.
Recursion Pharmaceuticals (NASDAQ: RXRX) stock rises after 20% workforce cut and pipeline reset
Recursion Pharmaceuticals (NASDAQ: RXRX) cuts 20% of workforce to extend runway and narrow pipeline focus—read what this means for its AI drug discovery strategy.
FPT advances digital healthcare strategy in Vietnam with AI-led public-private model
FPT Corporation launches AI-driven PPP framework to transform Vietnam’s healthcare system, aligning with Vision 2045 goals and digital health policy targets.
Can AI trial matching close the gap in cancer drug access?
Can AI fix clinical trial access in cancer care? Discover how Tempus, TrialJectory, and CureMatch are using intelligent platforms to democratize treatment pathways.
Q32 Bio’s bempikibart shows signs of a remittive effect in alopecia areata—Here’s what that means
Q32 Bio Inc. has released promising SIGNAL-AA trial results, shedding new light on the potential of bempikibart clinical…
Longeveron 2024 revenue jumps 237%, eyes FDA approval for Lomecel-B
Longeveron Inc., a biotechnology company specializing in regenerative medicine, has reported significant financial progress alongside major advancements in…
4D Molecular Therapeutics strengthens cash position, eyes Phase 3 success for 4D-150
4D Molecular Therapeutics (4DMT) has announced its full-year 2024 financial results, highlighting key advancements in its late-stage clinical…
Praxis Precision Medicines faces major setback in ulixacaltamide trial but remains committed to Essential3 study
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company specializing in treatments for central nervous system disorders, encountered…